Indeglitazar | PPM-204 | PLX-204 | CAS#835619-41-5

Indeglitazar
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 319853

CAS#: 835619-41-5

Description: Indeglitazar, also known as PPM-204 and PLX-204, is an orally available peroxisome proliferator-activated receptor (PPAR) pan-agonist for all three PPAR subtypes alpha (α), delta (δ) and gamma under development for for Type 2 diabetes mellitus (T2DM).

Chemical Structure

Indeglitazar

CAS# 835619-41-5

Product data Instruction

Theoretical Analysis

MedKoo Cat#: 319853
Name: Indeglitazar
CAS#: 835619-41-5
Chemical Formula: C19H19NO6S
Exact Mass: 389.09
Molecular Weight: 389.422
Elemental Analysis: C, 58.60; H, 4.92; N, 3.60; O, 24.65; S, 8.23

Price and Availability

Size	Price	Availability	Quantity
100mg	USD 450
200mg	USD 750
500mg	USD 1250
1g	USD 2150
2g	USD 3650
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Synonym: PLX-204; PLX204; PLX 204; PPM-204; PPM204; PPM 204; Indeglitazar

IUPAC/Chemical Name: 3-(5-Methoxy-1-((4-methoxyphenyl)sulfonyl)-1H-indol-3-yl)propanoic acid

InChi Key: YMPALHOKRBVHOJ-UHFFFAOYSA-N

InChi Code: InChI=1S/C19H19NO6S/c1-25-14-4-7-16(8-5-14)27(23,24)20-12-13(3-10-19(21)22)17-11-15(26-2)6-9-18(17)20/h4-9,11-12H,3,10H2,1-2H3,(H,21,22)

SMILES Code: O=C(O)CCC1=CN(S(=O)(C2=CC=C(OC)C=C2)=O)C3=C1C=C(OC)C=C3

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Product Data:

Product Data

Instruction:

View handling instruction

Biological target:	Indeglitazar (PPM 204) is an orally available PPAR pan-agonist for all three PPARα, PPARδ and PPARγ.
In vitro activity:	In an assay of preadipocyte differentiation, measuring in part functional insulin sensitization capability of the cells, indeglitazar showed an EC50 of 0.32 μM compared with rosiglitazone, which showed an EC50 of 0.013 μM, although the maximal response obtained from the 2 compounds was comparable (Fig. 2D). Reference: Proc Natl Acad Sci U S A. 2009 Jan 6;106(1):262-7. https://pubmed.ncbi.nlm.nih.gov/19116277/
In vivo activity:	Indeglitazar significantly decreased glucose, insulin, triglycerides, and free fatty acid levels (Table 3). These effects were comparable to pioglitazone on reducing glucose levels, triglycerides, and free fatty acids, although a significantly greater reduction of insulin levels were observed. As expected, pioglitazone increased adiponectin levels 3.5-fold, whereas indeglitazar raised adiponectin levels only 1.9-fold (Fig. 2F and Table 3). These data are consistent with the partial agonism observed in cell-based studies and also suggest that the insulin sensitizing activities of indeglitazar are at least partially independent of adiponectin. Reference: Proc Natl Acad Sci U S A. 2009 Jan 6;106(1):262-7. https://pubmed.ncbi.nlm.nih.gov/19116277/

Solubility Data

	Solvent	Max Conc. mg/mL	Max Conc. mM
Solubility
	DMSO	100.0	256.79

Preparing Stock Solutions

The following data is based on the product molecular weight 389.42 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:	1. Artis DR, Lin JJ, Zhang C, Wang W, Mehra U, Perreault M, Erbe D, Krupka HI, England BP, Arnold J, Plotnikov AN, Marimuthu A, Nguyen H, Will S, Signaevsky M, Kral J, Cantwell J, Settachatgull C, Yan DS, Fong D, Oh A, Shi S, Womack P, Powell B, Habets G, West BL, Zhang KY, Milburn MV, Vlasuk GP, Hirth KP, Nolop K, Bollag G, Ibrahim PN, Tobin JF. Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent. Proc Natl Acad Sci U S A. 2009 Jan 6;106(1):262-7. doi: 10.1073/pnas.0811325106. Epub 2008 Dec 30. PMID: 19116277; PMCID: PMC2629228.
In vitro protocol:	1. Artis DR, Lin JJ, Zhang C, Wang W, Mehra U, Perreault M, Erbe D, Krupka HI, England BP, Arnold J, Plotnikov AN, Marimuthu A, Nguyen H, Will S, Signaevsky M, Kral J, Cantwell J, Settachatgull C, Yan DS, Fong D, Oh A, Shi S, Womack P, Powell B, Habets G, West BL, Zhang KY, Milburn MV, Vlasuk GP, Hirth KP, Nolop K, Bollag G, Ibrahim PN, Tobin JF. Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent. Proc Natl Acad Sci U S A. 2009 Jan 6;106(1):262-7. doi: 10.1073/pnas.0811325106. Epub 2008 Dec 30. PMID: 19116277; PMCID: PMC2629228.
In vivo protocol:	1. Artis DR, Lin JJ, Zhang C, Wang W, Mehra U, Perreault M, Erbe D, Krupka HI, England BP, Arnold J, Plotnikov AN, Marimuthu A, Nguyen H, Will S, Signaevsky M, Kral J, Cantwell J, Settachatgull C, Yan DS, Fong D, Oh A, Shi S, Womack P, Powell B, Habets G, West BL, Zhang KY, Milburn MV, Vlasuk GP, Hirth KP, Nolop K, Bollag G, Ibrahim PN, Tobin JF. Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent. Proc Natl Acad Sci U S A. 2009 Jan 6;106(1):262-7. doi: 10.1073/pnas.0811325106. Epub 2008 Dec 30. PMID: 19116277; PMCID: PMC2629228.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Artis DR, Lin JJ, Zhang C, Wang W, Mehra U, Perreault M, Erbe D, Krupka HI,
England BP, Arnold J, Plotnikov AN, Marimuthu A, Nguyen H, Will S, Signaevsky M,
Kral J, Cantwell J, Settachatgull C, Yan DS, Fong D, Oh A, Shi S, Womack P,
Powell B, Habets G, West BL, Zhang KY, Milburn MV, Vlasuk GP, Hirth KP, Nolop K,
Bollag G, Ibrahim PN, Tobin JF. Scaffold-based discovery of indeglitazar, a PPAR
pan-active anti-diabetic agent. Proc Natl Acad Sci U S A. 2009 Jan
6;106(1):262-7. doi: 10.1073/pnas.0811325106. Epub 2008 Dec 30. PubMed PMID:
19116277; PubMed Central PMCID: PMC2629228.

Your view history

Indeglitazar featured